Chugai Pharmabody Research
Beverly Yang is a seasoned Principal Scientist at Chugai Pharmabody Research, with a career spanning roles as Project Leader and Disease Area Strategy Leader since March 2019. Prior experience includes serving as Senior Scientist II and Senior Scientist I in the Pharmacology Unit, where leadership in project development was pivotal. Before Chugai Pharmabody Research, Beverly Yang was a Postdoctoral Research Associate at the Mechanobiology Institute under Prof. Michael Sheetz, following a Research Assistant role with the same supervisor. Educational achievements include a Ph.D. in Mechanobiology from the National University of Singapore, complemented by a Visiting Scientist position at Columbia University, and a summer course at Institut Curie. Beverly Yang holds dual Bachelor of Science degrees in Econometrics and Quantitative Economics, alongside Biological Science from Xiamen University.
This person is not in any offices
Chugai Pharmabody Research
1 followers
In the global medical field, there are many diseases in which there are no drug or current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical in Japan, a member of Roche group, and is committed to address these unmet needs by specializing in the field of antibody drug discovery utilizing proprietary antibody engineering technologies.